(2S,5R,6R)-6-[[2-(3,4-dichlorophenyl)-2-methoxyacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酰胺类
• 英文名称: (2S,5R,6R)-6-[[2-(3,4-dichlorophenyl)-2-methoxyacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
• 化学式: C33H36Cl2N4O12S3
• 分子量: 847.8
• InChiKey: SFFACICIVBSVDT-YAURCHEJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.56
• 重原子数：
  54
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  296
• 氢给体数：
  5
• 氢受体数：
  14

文献信息

• ANTIBIOTIC METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS
  申请人：The University of Chicago

  公开号：EP2916653A1

  公开（公告）日：2015-09-16
• METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS
  申请人：THE UNIVERSITY OF CHICAGO

  公开号：US20160120852A1

  公开（公告）日：2016-05-05

  Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.
• US9675592B2
  申请人：——

  公开号：US9675592B2

  公开（公告）日：2017-06-13
• US9861619B2
  申请人：——

  公开号：US9861619B2

  公开（公告）日：2018-01-09
• [EN] ANTIBIOTIC METHODS AND COMPOSITIONS FOR BACTERIA INFECTIONS<br/>[FR] MÉTHODES ANTIBIOTIQUES ET COMPOSITIONS D'ANTIBIOTIQUE POUR DES INFECTIONS BACTÉRIENNES
  申请人：UNIV CHICAGO

  公开号：WO2014071198A1

  公开（公告）日：2014-05-08

  Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.